Management guidelines and outcome measures in giant cell arteritis (PMR)

Clinical and Experimental Rheumatology

Volumn 25, Issue 6 SUPPL. 47, 2007, Pages

  Warrington, Kenneth J ^a   Matteson, Eric L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Aneursym; Corticosteroids; Giant cell arteritis; Polymyalgia rheumatica headache; Vasculitis

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ATOVAQUONE; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; FOLIC ACID; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INFLIXIMAB; INFLUENZA VACCINE; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PNEUMOCOCCUS VACCINE; PREDNISONE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VITAMIN D;

AORTA ANEURYSM; ARTICLE; BLOOD VESSEL BIOPSY; BONE DENSITY; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CLINICAL TRIAL; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; FOLLOW UP; GIANT CELL ARTERITIS; HUMAN; HYPERTENSION; LABORATORY TEST; LOW DRUG DOSE; MONITORING; OSTEOLYSIS; OUTCOMES RESEARCH; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RELAPSE; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; STROKE; SYMPTOM; TEMPORAL ARTERY; VASCULITIS; VISUAL IMPAIRMENT;

BIOPSY; BONE DENSITY; FOLLOW-UP STUDIES; GIANT CELL ARTERITIS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; STEROIDS; TREATMENT OUTCOME;

EID: 36448929143     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. SALVARANI C, CROWSON CS, O'FALLON WM, HUNDER GG, GABRIEL SE: Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum 2004; 51: 264-8.
2. SALVARANI C, GABRIEL SE, O'FALLON WM, HUNDER GG: The incidence of giant cell arteritis in Olmsted County, Minnesota: Apparent fluctuations in a cyclic pattern. Ann Intern Med 1995; 123: 192-4.
3. WEYAND CM, GORONZY JJ: Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 2003; 139: 505-15.
4. SALVARANI C, CANTINI F, BOIARDI L, HUNDER GG: Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347: 261-71.
5. HUNDER GG, BLOCH DA, MICHEL BA et al.: The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122-8.
6. SMETANA GW, SHMERLING RH: Does this patient have temporal arteritis? JAMA 2002; 287: 92-101.
7. KARASSA FB, MATSAGAS MI, SCHMIDT WA, IOANNIDIS JP: Meta-analysis: Test performance of ultrasonography for giant-cell arteritis. Ann Intern Med 2005; 142: 359-69.
8. SCHMIDT WA, KRAFT HE, VORPAHL K, VOLKER L, GROMNICA-IHLE EJ: Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997; 337: 1336-42.
9. BLEY TA, WEIBEN O, UHL M et al.: Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging. Arthritis Rheum 2005; 52: 2470-7.
10. BONGARTZ T, MATTESON EL: Large-vessel involvement in giant cell arteritis. Curr Opin Rheumatol 2006; 18: 10-7.
11. 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: A prospective study of 35 patients. Arthritis Rheum 2006; 55: 131-7.
12. BIRKHEAD NC, WAGENER HP, SHICK RM: Treatment of temporal arteritis with adrenal corticosteroids; results in fifty-five cases in which lesion was proved at biopsy. J Am Med Assoc 1957; 163: 821-7.
13. HUNDER GG, SHEPS SG, ALLEN GL, JOYCE JW: Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: Comparison in a prospective study. Ann Intern Med 1975; 82: 613-8.
14. CHAN CC, PAINE M, O'DAY J: Steroid management in giant cell arteritis. Br J Ophthalmol 2001; 85: 1061-4.
15. ACHKAR AA, LIE JT, HUNDER GG, O'FALLON WM, GABRIEL SE: How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994; 120: 987-92.
16. RAY-CHAUDHURI N, KINE DA, TIJANI SO et al.: Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthalmol 2002; 86: 530-2.
17. LEE MS, SMITH SD, GALOR A, HOFFMAN GS: Anti-platelet and anti-coagulant therapy in patients with giant cell arteritis. Arthritis Rheum 2006; 54: 3306-9.
18. NESHER G, BERKUN Y, MATES M, BARAS M, RUBINOW A, SONNENBLICK M: Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004; 50: 1332-7.
19. KYLE V, HAZLEMAN BL: Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis 1989; 48: 662-6.
20. YALE SH, LIMPER AM: Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: Associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996; 71: 5-13.
21. EVANS JM, O'FALLON WM, HUNDER GG: Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 1995; 122: 502-7.
22. NUENNINGHOFF DM, HUNDER GG, CHRISTIANSON TJ, MCCLELLAND RL, MATTESON EL: Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: A population-based study over 50 years. Arthritis Rheum 2003; 48: 3532-7.
23. NUENNINGHOFF DM, HUNDER GG, CHRISTIANSON TJ, MCCLELLAND RL, MATTESON EL: Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: A population-based study over 50 years. Arthritis Rheum 2003; 48: 3522-31.
24. HERNANDEZ-RODRIGUEZ J, GARCIA-MARTINEZ A, CASADEMONT J et al.: A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum 2002; 47: 29-35.
25. JOVER JA, HERNANDEZ-GARCIA C, MORADO IC, VARGAS E, BANARES A, FERNANDEZ-GUTIERREZ B: Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134: 106-14.
26. HOFFMAN GS, CID MC, HELLMANN DB et al: A multi-center, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002; 46: 1309-18.
27. MAHR AD, JOVER JA, SPIERA RF et al.: Adjunctive methotrexate to treat giant cell arteritis: An individual patient data meta-analysis. In 13th International Vasculitis & ANCA Workshop, 2007, Cancun, Mexico.
28. DE SILVA M, HAZLEMAN BL: Azathioprine in giant cell arteritis/ polymyalgia rheumatica: A double-blind study. Ann Rheum Dis 1986; 45: 136-8.
29. SCHAUFELBERGER C, MOLLBY H, UDDHAMMAR A, BRATT J, NORDBORG E: No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. Scand J Rheumatol 2006; 35: 327-9.
30. NUENNINGHOFF DM, MATTESON EL: The role of disease-modifying anti-rheumatic drugs in the treatment of giant cell arteritis. Clin Exp Rheumatol 2003; 21 (Suppl. 32): S29-34.
31. CANTINI F, NICCOLI L, SALVARANI C, PADULA A, OLIVIERI I: Treatment of longstanding active giant cell arteritis with infliximab: Report of four cases. Arthritis Rheum 2001; 44: 2933-5.
32. AHMED MM, MUBASHIR E, HAYAT S, FOWLER M, BERNEY SM: Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol 2007; 26: 1353-5.
33. HOFFMAN GS, CID MC, RENDT-ZAGAR KE et al.: Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: A randomized trial. Ann Intern Med 2007; 146: 621-30.
34. MAZLUMZADEH M, HUNDER GG, EASLEY KA et a.: Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: A double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 2006; 54: 3310-8.